Polymedco, Inc.
http://www.polymedco.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Polymedco, Inc.
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Gilead Gets License To Compugen’s Potential First-In-Class IL-18 Target For Cancer
The company will pay $60m for rights to the preclinical asset COM503, which could be a new type of immuno-oncology drug.
Finance Watch: Big Financings Show Investors Remain Interested In Certain Opportunities
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
Gilead Partners With Tentarix In Platform Discovery Deal
Deal Snapshot: Gilead will collaborate with the start-up on the discovery and development of first-in-class targeted, multifunctional, conditional therapeutics.
Company Information
- Industry
- Distributors
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Hematology, Coagulation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice